Mercado mundial de administración de fármacos pulmonares: tendencias de la industria y pronóstico hasta 2030

Análisis y tamaño del mercado de administración de fármacos pulmonares

El objetivo principal de la vía de administración de fármacos, conocida como administración pulmonar de fármacos, es depositar los agentes farmacológicos inhalados en las vías respiratorias inferiores con dispositivos que ayudan a inhalar las formulaciones de fármacos a través de la boca. Se utilizan ampliamente en diversas industrias de usuarios finales, incluidos hospitales, clínicas y entornos de atención domiciliaria. Se utilizan numerosos dispositivos para la administración respiratoria, incluidos nebulizadores, inhaladores de dosis medida e inhaladores de polvo seco. Los beta-agonistas inhalados, los corticosteroides y los medicamentos anticolinérgicos se administran a través de los pulmones para tratar el asma y la enfermedad pulmonar obstructiva crónica (EPOC). La vía de administración pulmonar tiene varias ventajas. El medicamento se administra directamente en el lugar de la enfermedad para tratar enfermedades respiratorias.

Data Bridge Market Research analiza que el mercado de administración de fármacos pulmonares, valorado en USD 47,85 mil millones en 2022, alcanzará los USD 72,88 mil millones para 2030, creciendo a una CAGR del 5,4% durante el período de pronóstico de 2023 a 2030. Además de los conocimientos sobre escenarios de mercado como el valor de mercado, la tasa de crecimiento, la segmentación, la cobertura geográfica y los principales actores, los informes de mercado seleccionados por Data Bridge Market Research también incluyen un análisis profundo de expertos, epidemiología de pacientes, análisis de cartera, análisis de precios y marco regulatorio.

Alcance y segmentación del mercado de administración de fármacos pulmonares  

Definición de mercado

La administración dirigida del fármaco al lugar de destino se denomina "administración dirigida del fármaco". Un sistema de administración dirigida del fármaco, denominado administración pulmonar del fármaco, requiere que la fracción del fármaco se dirija hacia el tracto respiratorio inferior. Un dispositivo utilizado para administrar medicamentos al cuerpo por vía pulmonar se denomina sistema de administración pulmonar del fármaco. La vía de inhalación ofrece una alternativa superior a la administración oral para tratar el asma y la enfermedad pulmonar obstructiva crónica. La acción instantánea de la administración pulmonar del fármaco alivia la bronquitis aguda y los ataques asmáticos. Para la administración pulmonar del fármaco, los aerosoles son dispositivos especialmente fabricados.

Dinámica del mercado de administración de fármacos para uso pulmonar

Conductores

• La creciente prevalencia de crisis respiratorias graves aumenta la demanda

 La creciente prevalencia de enfermedades respiratorias graves, como la fibrosis quística y la enfermedad pulmonar obstructiva crónica, está impulsando el crecimiento del mercado de administración de fármacos pulmonares. Además, la creciente demanda de tratamientos mínimamente invasivos y efectivos y la tendencia al alza de la administración de fármacos pulmonares debido a las características de una gran área porosa, una membrana mucosa absorbente delgada y un suministro de sangre eficiente impulsarán el crecimiento del mercado. Además, la creciente prevalencia del tabaquismo puede afectar a las enfermedades respiratorias, acelerando aún más el crecimiento general del mercado.

•  La prevalencia de enfermedades pulmonares impulsa el mercado

El aumento de la contaminación del aire, la prevalencia de enfermedades pulmonares como el asma y la enfermedad pulmonar obstructiva crónica, ha puesto de manifiesto el creciente número de hospitales y centros de diagnóstico, el aumento de la financiación de organizaciones privadas y públicas para el tratamiento de enfermedades pulmonares y el aumento de la conciencia pública sobre la salud pulmonar, que son los principales factores que impulsan el mercado mundial de sistemas de administración de fármacos pulmonares. La Organización Mundial de la Salud informa que 9 de cada 10 personas respiran aire que contiene altos niveles de contaminantes y las estimaciones indican que en 2018, la contaminación del aire ambiental (exterior) y doméstico será responsable de una alarmante cifra de 7 millones de muertes anuales.

Oportunidades

• Las compras en línea, como resultado del desarrollo tecnológico, impulsan el mercado

Emerging markets and online channels are anticipated to expand and experience technological advancements to open up profitable market opportunities. The trend and demand for online shopping are growing due to its comfort, adaptability, and convenience, boosting the revenue generated by this market. Customers can also get discounts when they shop online. Additionally, the sum of these factors will increase demand for online pharmacies, and the advantages such as low cost and quick preparation and administration times, will persuade users to use these inhalers more frequently. Thus, with the technological advancements that have made dry powder inhalers a preferred medical device for treating various respiratory disorders, the use of these products has increased. Thus it will help in the expansion of the market.

• Hospital pharmacies are more trustable by people, which creates expansion in market

The segment of hospital pharmacies held the most significant percentage of the patient-determined disease steps and is anticipated to maintain that position going forward. Patients favor hospital pharmacies because they offer comprehensive medical care, quick reimbursements, and insurance policies. In addition, a rise in hospitalizations is anticipated to spur this market's expansion

Restraints/Challenges

• Lack of knowledge prevents the market from expansion

Drugs' expiring patents and general ignorance could obstruct the market's expansion. The general public's lack of knowledge about nasal drug delivery methods hinders market expansion. The technique for administering the doses must be explained to the patients. This limits the market's expansion for pulmonary drug delivery systems. The overall market revenue is hindered during the forecast period by inadequate training, a lack of understanding, and improper usage.

• High costs and strict regulations may limit the market

The market is growing due to numerous healthcare foundations and government initiatives for treating pulmonary diseases. However, the market is constrained by the high costs associated with pulmonary drug delivery system devices. The potential for implanted device failures and inadequate reimbursement in developed economies hampers the market's expansion. The growth of the overall market is also hampered by the strict regulatory policies for procedures and the high cost of treatment.

This pulmonary drug delivery market  report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the pulmonary drug delivery market contact Data Bridge Market Research for an analyst brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In 2022, Subintro's acquisition by RIGImmune gave it access to cutting-edge topical delivery systems. With this agreement, the biotech is better positioned to advance the creation of cutting-edge RNA therapies and vaccine adjuvants for local mucosal delivery.
• In 2022, Orbital Dry Powder Inhaler (DPI) worldwide license was acquired by Aptar Pharma. This acquisition will enable Aptar Pharma to meet the rising demand for easy and secure high-dose lung treatment administration.
• In 2020, The U.S. Food and Drug Administration (FDA) received a New Drug Application (NDA) for UPTRAVI (selexipag) as an intravenous (IV) injection to treat pulmonary arterial hypertension from Johnson & Johnson's Janssen Pharmaceutical Companies.
• In 2020, The Japanese Ministry of Health, Labour, and Welfare (MHLW) simultaneously approved new treatment options for Japanese patients, according to news released by Novartis Pharma K.K. ("Novartis Pharma"). For advanced and recurrent untreatable non-small cell lung cancer (NSCLC) with MET exon 14 skipping (METex14) mutation, TabrectaTM (capmatinib, formerly INC280) is an oral MET inhibitor.

Global Pulmonary Drug Delivery Market Scope

The pulmonary drug delivery market is segmented on the basis of formulations, canister type, application, and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Formulations

• Type
• Suspension aerosol
• Solution Aerosal
• Dry power formulation
• Device type
• Dry Powder Inhalers
• Single-Dose Inhalers
• Multi-Dose Inhaler
• Metered Dose Inhalers
• Manually-Actuated Pressurized Inhaler
• Breath-Actuated Pressurized Inhaler
• Nebulizers
• Jet Nebulizers
• Soft Mist Nebulizers
• Ultra Wave Nebulizers
• Mesh
• Vibrating
• Static
• Pneumatic
• Vented
• Breath Actuated
• Accessories

Canister Type

• Plain Canister
• Coated Canister

Application

• Chronic Obstructive Pulmonary Disease (COPD)
• Asthma
• Cystic Fibrosis
• Allergic Rhinitis
• Other

End-User

• Hospitals and Clinics
• Home Care Settings

Pulmonary Drug Delivery Market Regional Analysis/Insights

The pulmonary drug delivery market is analysed and market size insights and trends are provided by country, formulations, canister type, application, and end-user as referenced above.

The countries covered in the pulmonary drug delivery market  report are  U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the market due to the growing prevalence of respiratory and lung disorders, technological advancement, and increasing awareness. Furthermore, through an increase in the prevalence of pulmonary diseases, the presence of major players in the production and development of drugs for pulmonary diseases, an increase in the number of hospitals and diagnostic facilities, and government initiatives for treating pulmonary diseases in the area.

Asia-Pacific is expected to show a rapid and lucrative growth rate in the forecast period owing to Japan's increasing disposable and rising geriatric population. Moreover, the rising patient count with respiratory and acceptance of pulmonary drug devices will boost the region market, whereas increasing government initiatives to improve healthcare infrastructure will also expand market growth.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Pulmonary Drug Delivery Market Share Analysis

The pulmonary drug delivery market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to pulmonary drug delivery market.

Some of the major players operating in the pulmonary drug delivery market are:

• F. Hoffmann-La Roche Ltd (Suiza)
• Corporación MannKind (Estados Unidos)
• OMRON Healthcare, Inc. (Japón)
• Mylan NV (Estados Unidos)
• 3M (Estados Unidos)
• Koninklijke Philips NV (Países Bajos)
• Merck & Co., Inc., (Estados Unidos)
• Industrias farmacéuticas Teva Ltd. (Israel)
• Sunovion Pharmaceuticals Inc. (Estados Unidos)
• PARI GmbH (Alemania)
• Jabil Inc. (Estados Unidos)
• AstraZeneca (Reino Unido)
• Boehringer Ingelheim International GmbH (Alemania)
• GSK plc. (Reino Unido)
• Novartis AG (Suiza)
• Aerogen Pharma (Irlanda)
• Briggs Healthcare (Estados Unidos)
• GRUPO HAAG-STREIT (Suiza)
• Janssen Global Services, LLC (Estados Unidos)
• AptarGroup, Inc. (Estados Unidos)

SKU-12286